Gantenerumab

Type: Product
Name: Gantenerumab
First reported Aug 12 2014 - Updated Aug 12 2014 - 1 reports

MorphoSys reports net loss for Q2, reaffirms annual guidance

MorphoSys AG, a German biotechnology company, has reported that net loss for the second quarter ended June 30, 2014 was E526.746, or E0.02 loss per diluted share, compared to a net profit of E11.11 million, or E0.47 per diluted share, for the same quarter ... [Published Individual.com - Aug 12 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 1 reports

Almirall seeks dermatology deals, Euro biotech IPOs fall short, Cellectis increases CAR-T focus

Welcome to the latest edition of our weekly EuroBiotech Report . The last week of July was a massive one for European biotech IPOs, with BioBlast Pharma ($ORPN), Innocoll ( $INNL) , Macrocure ( $MCUR ), Mapi Pharma and VBL Therapeutics ($VBLX) all heading ... [Published FierceBiotech - Jul 31 2014]
First reported Jul 28 2014 - Updated Jul 29 2014 - 1 reports

MorphoSys AG Reports Results for the First Six Months of 2014

(GLOBE NEWSWIRE) -- (FSE: MOR; Prime Standard Segment; TecDAX, OTC: MPSYY) today announced its financial results for the six months ending 30 June 2014. Group revenues from continuing operations were EUR 30.5 million (H1 2013: EUR 48.2 million). Reasons ... [Published Pettinga Financial Advisors - Jul 28 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 2 reports

MorphoSys highlights pipeline as Q2 shows loss

MorphoSys AG reported a loss for the second quarter due largely to an unfavourable comparison with the previous period when earnings were inflated by a licensing deal with GlaxoSmithKline Plc. However, the company expects its loss for the year as a whole ... [Published MedNous - Jul 28 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

Alzheimer’s therapies could result in $12B market by 2023

The industry for Alzheimer’s drug treatments is expected to grow from modest beginnings to big business in the next decade, according to a June report by Decision Resources Group.The analysis estimates that the market for Alzheimer’s therapies will more ... [Published MolecularImaging.net - Jul 28 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Diabetes Drug Linked to Lower Dementia Risk

COPENHAGEN, Denmark — Long-term use of the diabetes drug pioglitazone ( Actos , Takeda Pharmaceuticals) may protect against dementia, an observational study suggests.The study was presented here at the Alzheimer's Association International Conference ... [Published American Journal of Public Health - Jul 24 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 3 reports

Alzheimer’s Drug Market Predicted to Triple, Reaching Nearly $12 Billion, by 2023

Blockbuster status awaits novel disease-modifying therapiesDecision Resources Group, a health care research firm located in Burlington, Mass., finds that the market for Alzheimer’s disease (AD) therapies will more than triple, reaching nearly $12 billion, ... [Published PT Community - Jul 22 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

Roche announces phase II clinical results of crenezumab in Alzheimer’s disease

Details Category: Antibodies Published on Thursday, 17 July 2014 11:33 Hits: 207    Proof of concept study in mild-to-moderate Alzheimer’s disease did not meet its co-primary endpointsPositive trend in cognition observed with greater effect in people ... [Published PipelineReview - Jul 18 2014]
First reported Jul 15 2014 - Updated Jul 16 2014 - 5 reports

5 Groundbreaking Drugs That May Prevent Alzheimer’s

Researchers are testing some promising drug candidates to halt Alzheimer’s dementia – even before symptoms startAt the Alzheimer’s Association International Conference in Copenhagen, scientists described five trials that taking the unprecedented step ... [Published Time - Jul 16 2014]
First reported Jul 16 2014 - Updated Jul 16 2014 - 1 reports

Novartis launches Alzheimer’s prevention study

Novartis announced yesterday it intends to find out if two of its drugs can prevent Alzheimer's disease in people who have a genetic risk of developing the condition.The pharma company will work with Banner Alzheimer's Institute (BAI) on a study involving ... [Published PMLive - Jul 16 2014]
First reported Mar 02 2014 - Updated Mar 02 2014 - 1 reports

Delivery system for cytotoxic drugs by bispecific antibody pretargeting

The present invention relates to methods and compositions for pretargeting delivery of therapeutic agents. In preferred embodiments, the pretargeting method comprises: a) administering a bispecific antibody with a first binding site for a disease-associated ... [Published PharmCast - Mar 02 2014]

Quotes

...55 million, compared to E48.23 million for the same period ended June 30, 2013. Jens Holstein, CFO of MorphoSys AG, said: "We are pleased with the first half of 2014 and are on track to meet our goals for the full year. With the first-time disclosure of a royalty rate for our HuCAL antibody gantenerumab we are able to provide more visibility on the long-term revenue potential of our partnered compounds."
The European Commission approved Veloxis Pharmaceuticals " (OMX:VELO) Envarsus for preventing organ rejection in adult kidney and liver transplant patients. Italian firm Chiesi Farmaceutici will commercialize the drug in the European Union. Release"
"The second quarter saw excellent progress with regard to partnering our latest Ylanthia antibody technology. With Merck Serono and the Temple University's Moulder Center for Drug Discovery two new alliances were initiated that have the potential to expand our pipeline of exciting new drug candidates" stated Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG
"One key goal of this collaboration is for the researchers to make the data from the separate trials more comparable. We believe this will increase the amount that scientists can learn both from each individual trial and from comparing results across the trials" he said

More Content

All (18) | News (17) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
MorphoSys reports net loss for Q2, reaffirms an... [Published Individual.com - Aug 12 2014]
Almirall seeks dermatology deals, Euro biotech ... [Published FierceBiotech - Jul 31 2014]
MorphoSys highlights pipeline as Q2 shows loss [Published MedNous - Jul 28 2014]
MorphoSys' (MPSYF) CEO Simon Moroney on Q2 2014... [Published Seeking Alpha - Jul 28 2014]
Alzheimer’s therapies could result in $12B mark... [Published MolecularImaging.net - Jul 28 2014]
MorphoSys AG Reports Results for the First Six ... [Published Pettinga Financial Advisors - Jul 28 2014]
Diabetes Drug Linked to Lower Dementia Risk [Published American Journal of Public Health - Jul 24 2014]
Alzheimer’s Drug Market Predicted to Triple, Re... [Published PT Community - Jul 22 2014]
Alzheimer's drug market 'set to triple by 2023' [Published Pharma Times - Jul 22 2014]
Alzheimer's disease market forecast to reach ne... [Published Center Watch - Jul 22 2014]
Roche announces phase II clinical results of cr... [Published PipelineReview - Jul 18 2014]
5 Groundbreaking Drugs That May Prevent Alzheim... [Published Time - Jul 16 2014]
5 Groundbreaking Drugs That May Prevent Alzheim... [Published TIME.com - Jul 16 2014]
Roche announces phase II clinical results of cr... [Published Noodls - Jul 16 2014]
Roche Alzheimer's drug fails main goals in mid-... [Published CNBC - Jul 16 2014]
Novartis launches Alzheimer’s prevention study [Published PMLive - Jul 16 2014]
Can Roche Find Rare Success In Alzheimer's? [Published Motley Fool Discussion Boards - Jul 15 2014]
Delivery system for cytotoxic drugs by bispecif... [Published PharmCast - Mar 02 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
5 Groundbreaking Drugs That May Prevent Alzheim... [Published TIME.com - Jul 16 2014]
At the Alzheimer’s Association International Conference in Copenhagen, scientists described five trials that taking the unprecedented step of testing drugs that may prevent the onset of the neurodegenerative disease in people not yet experiencing cognitive ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.